AR105106A1 - DERIVATIVES OF 1,3-OXAZIN-4-ONA AS ALLOSTERIC MODULATORS OF THE M1 MOLINARY MUSCARINIC RECEIVER - Google Patents
DERIVATIVES OF 1,3-OXAZIN-4-ONA AS ALLOSTERIC MODULATORS OF THE M1 MOLINARY MUSCARINIC RECEIVERInfo
- Publication number
- AR105106A1 AR105106A1 ARP160101884A ARP160101884A AR105106A1 AR 105106 A1 AR105106 A1 AR 105106A1 AR P160101884 A ARP160101884 A AR P160101884A AR P160101884 A ARP160101884 A AR P160101884A AR 105106 A1 AR105106 A1 AR 105106A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- optionally substituted
- molinary
- oxazin
- ona
- Prior art date
Links
- 230000003281 allosteric effect Effects 0.000 title abstract 2
- 230000003551 muscarinic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- -1 2,4-dioxothiazolidin-5-yl Chemical group 0.000 abstract 1
- HQQTZCPKNZVLFF-UHFFFAOYSA-N 4h-1,2-benzoxazin-3-one Chemical compound C1=CC=C2ONC(=O)CC2=C1 HQQTZCPKNZVLFF-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000009829 Lewy Body Disease Diseases 0.000 abstract 1
- 201000002832 Lewy body dementia Diseases 0.000 abstract 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 abstract 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 230000001713 cholinergic effect Effects 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000020685 sleep-wake disease Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000005750 substituted cyclic group Chemical group 0.000 abstract 1
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un compuesto con una actividad moduladora alostérica positiva del receptor muscarínico colinérgico M1, que puede ser útil como un fármaco preventivo o terapéutico para enfermedad de Alzheimer, esquizofrenia, dolor, trastorno del sueño, demencia por enfermedad de Parkinson, demencia por cuerpos de Lewy, y similares. Reivindicación 1: Un compuesto representado por la fórmula (1) caracterizado porque R¹ y R² son cada uno, de modo independiente, un átomo de hidrógeno o un sustituyente o una estructura parcial de fórmula (2) es opcionalmente un compuesto de fórmula (3) (en donde X¹ y X² son cada uno, de modo independiente, CH o N); R³ es un átomo de hidrógeno, un grupo alquilo C₁₋₆ opcionalmente sustituido o un grupo cíclico opcionalmente sustituido y el anillo A es un anillo que también está opcionalmente sustituido, excluyendo 6-[(2,4-dioxotiazolidin-5-il)metil]-3-[(4-trifluorometil)fenil)metil]-1,3-benzoxazin-4-ona o una de sus sales.A compound with a positive allosteric modulating activity of the M1 cholinergic muscarinic receptor, which may be useful as a preventive or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia, and Similar. Claim 1: A compound represented by the formula (1) characterized in that R¹ and R² are each, independently, a hydrogen atom or a substituent or a partial structure of formula (2) is optionally a compound of formula (3) (where X¹ and X² are each, independently, CH or N); R³ is a hydrogen atom, an optionally substituted C₁₋₆ alkyl group or an optionally substituted cyclic group and ring A is a ring that is also optionally substituted, excluding 6 - [(2,4-dioxothiazolidin-5-yl) methyl ] -3 - [(4-trifluoromethyl) phenyl) methyl] -1,3-benzoxazin-4-one or one of its salts.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015129043 | 2015-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105106A1 true AR105106A1 (en) | 2017-09-06 |
Family
ID=59981587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160101884A AR105106A1 (en) | 2015-06-26 | 2016-06-23 | DERIVATIVES OF 1,3-OXAZIN-4-ONA AS ALLOSTERIC MODULATORS OF THE M1 MOLINARY MUSCARINIC RECEIVER |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR105106A1 (en) |
| EC (1) | ECSP18006622A (en) |
-
2016
- 2016-06-23 AR ARP160101884A patent/AR105106A1/en unknown
-
2018
- 2018-01-26 EC ECIEPI20186622A patent/ECSP18006622A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP18006622A (en) | 2018-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR100154A1 (en) | HETEROCYCLIC COMPOUND CONTAINING NITROGEN | |
| UY36750A (en) | HETEROCYCLIC COMPOUND | |
| AR095823A1 (en) | CYCLOPROPANAMINE COMPOUND AND USE OF THE SAME | |
| PE20190653A1 (en) | NEW DERIVATIVES OF PIRROL, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| AR070558A1 (en) | DERIVATIVES OF 7-PHENYL-7H-PIRROLO- [2,3D] -PIRIMIDIN-2-IL-AMINO, PROCESS TO PREPARE THEM, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND USE OF THEM FOR THE TREATMENTS OF TIROSINQUINASAS DISEASE, TYPES PROLIFERATIVES | |
| MX2016001011A (en) | Substituted quinazolin-4-one derivatives. | |
| AR095885A1 (en) | COMPOUNDS DERIVED FROM ARILPIRROLOPIRIDINA AS INHIBITORS OF LRRK2 | |
| UY35377A (en) | 1,3-OXAZIN-2-AMINA COMPOUNDS FUSED WITH PERFLUORATED CYCLOPROPYL AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | |
| PE20190446A1 (en) | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLIN RECEPTOR M4 | |
| AR115015A1 (en) | DERIVATIVES OF AZAESPIRO PIPERAZINE | |
| PE20181851A1 (en) | NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS | |
| TW201613890A (en) | Pyridine derivatives as muscarinic M1 receptor positive allosteric modulators | |
| PE20160050A1 (en) | INHIBITORS / ANTIANDROGENS NOVEL CYP17 | |
| CY1125225T1 (en) | 6-MEMBERED AZA-HETEROCYCLES CONTAINING DELTA-OPIOID RECEPTOR MODIFYING COMPOUNDS, METHODS OF USE AND PRODUCTION THEREOF | |
| MX2018014944A (en) | Treatment for parkinson's disease. | |
| PE20160666A1 (en) | ETHINYL DERIVATIVES | |
| AR105106A1 (en) | DERIVATIVES OF 1,3-OXAZIN-4-ONA AS ALLOSTERIC MODULATORS OF THE M1 MOLINARY MUSCARINIC RECEIVER | |
| MX2016015627A (en) | COMPOSITE OF THIAZOLIDINONE AND ITS USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND OF INFLAMMATION, IN PARTICULAR OF THE NEUROINFLAMATION. | |
| AR094381A1 (en) | BENZODIOXAN-PIPERIDINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | |
| AR096563A1 (en) | HETEROCYCLIC COMPOUND | |
| AR110406A1 (en) | 6-AMINO-5-FLUORO-5- (FLUOROMETIL) -2,3,4,5-TETRAHIDROPIRIDIN-2-IL-FENIL-5- (METOXI-D₃) -PIRAZINA-2-CARBOXAMIDS AND FLUORATED DERIVATIVES OF THE SAME AS BACE1 INHIBITORS | |
| AR101070A1 (en) | SULFONAMIDE COMPOUNDS AS REGULATED VOLTAGE SOUND CHANNEL MODULATORS | |
| AR099402A1 (en) | CYCLOPROPILAMINS AS INHIBITORS OF LSD1 | |
| PL400584A1 (en) | Medical use of 3-(thiophen-2-yl)-1,2,4-triazole-5-thione |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |